ENDARI

Peak

glutamine

NDAORALFOR SOLUTION
Approved
Jul 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
8

Mechanism of Action

L-glutamine in treating sickle cell disease (SCD) is not fully understood. Oxidative stress phenomena are involved in the pathophysiology of SCD. Sickle red blood cells (RBCs) are more susceptible to oxidative damage than normal RBCs, which may contribute to the chronic hemolysis and vaso-occlusive…

Pharmacologic Class:

Amino Acid

Clinical Trials (5)

NCT04019184Phase 3Completed

Reduction of Occurence of Acute Kidney Injury (AKI) Through Administration of Glutamine

Started Jul 2019
64 enrolled
Cardiac SurgeryAcute Kidney Injury
NCT01552291Phase 4Completed

The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies

Started May 2012
42 enrolled
MalnourishmentGastrointestinal Tumors
NCT01087658Phase 3Completed

Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity

Started Feb 2010
200 enrolled
Colorectal Neoplasms
NCT00913692Phase 2Terminated

A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis

Started Jun 2009
NCT00133978N/ACompleted

Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients

Started Apr 2005
1,223 enrolled
Critical IllnessSepsisMultiple Organ Failure